Stockreport

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome [Yahoo! Finance]

AC Immune SA  (ACIU) 
Last ac immune sa earnings: 11/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
PDF ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug No cases of amyloid-relate [Read more]